Riluzole, a glutamate release inhibitor, and motor behavior

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Naunyn-Schmiedeberg's Archives of Pharmacology

• Publication date

  1998-08-04

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1007/PL00005241PMID 9750003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Riluzole

  2019influential reference
• Ligands of the NMDA receptor-associated glycine recognition site and motor behavior

  2005cited by this paper
• The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

  2005cited by this paper
• Glycine site antagonists abolish dopamine D 2 but not D 1 receptor mediated catalepsy in rats

  2005cited by this paper
• A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice

  2005cited by this paper
• MK-801-induced stereotypy and its antagonism by neuroleptic drugs

  2005cited by this paper
• The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior

  2005cited by this paper
• Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats

  2005cited by this paper
• D1/D2 dopamine and N-methyl-d-aspartate (NMDA) receptor participation in experimental catalepsy in rats

  2005cited by this paper
• Intrastriatal injection of dl-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine

  2004cited by this paper
• The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy

  2004cited by this paper
• GlycineB antagonists as potential therapeutic agents

  1998cited by this paper
• ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats.

  1997cited by this paper
• Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism

  1997cited by this paper
• Behavioral effects mediated by the modulatory glycine site of the NMDA receptor in the anterodorsal striatum and nucleus accumbens

  1996cited by this paper
• Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis

  1996cited by this paper
• The pharmacology and mechanism of action of riluzole

  1996influential reference
• The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.

  1996cited by this paper
• Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions.

  1996cited by this paper
• Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group.

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

  1996cited by this paper
• Safety, Tolerability, and Pharmacokinetics of the N-Methyl-d-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke

  1995cited by this paper
• Clinical experience with excitatory amino acid antagonist drugs.

  1995cited by this paper
• Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.

  1995cited by this paper
• Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.

  1995cited by this paper
• Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group.

  1995cited by this paper
• Riluzole and experimental parkinsonism: partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo

  1994cited by this paper
• Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole.

  1994cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper
• Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers.

  1994cited by this paper
• The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.

  1994cited by this paper
• Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats.

  1994cited by this paper
• Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes.

  1994cited by this paper
• Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.

  1994cited by this paper
• Glutamate antagonists have different effects on spontaneous locomotor activity in rats.

  1994influential reference
• Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination.

  1994cited by this paper
• The pharmacology of SDZ EAA 494, a competitive NMDA antagonist.

  1994cited by this paper
• The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine

  1993cited by this paper
• Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.

  1993cited by this paper
• Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.

  1993influential reference
• Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists.

  1993cited by this paper
• NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens.

  1993cited by this paper
• Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity

  1993cited by this paper
• Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats.

  1992cited by this paper
• The NMDA receptor antagonist CPP abolishes neurogenic “wind-up pain” after intrathecal administration in humans.

  1992cited by this paper
• Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks.

  1990cited by this paper
• Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential.

  1990cited by this paper
• Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors.

  1989cited by this paper
• Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats.

  1989cited by this paper
• Ibotenic acid stimulates D-[3H]aspartate release from cultured cerebellar granule cells.

  1989cited by this paper
• Role of quisqualic acid receptors in the hypermotility response produced by the injection of AMPA into the nucleus accumbens.

  1988cited by this paper
• Anticonvulsant activity of (+)‐5‐methyl‐10, 11‐dihydro‐5H‐dibenzo[a, d]cyclohepten‐5, 10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties

  1982cited by this paper
• Behavioural functions of GABA in basal ganglia and limbic system

  1979cited by this paper
• Model psychoses and schizophrenia.

  1962cited by this paper

• Hemin-functionalised conducting polymer as a unique host matrix for the electrochemical synthesis of benzothiazole derivatives: A sustainable approach

  2026cites this paper
• ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole

  2026cites this paper
• IUPHAR review: Drug Repurposing in Schizophrenia - An Updated Review of Clinical Trials.

  2025cites this paper
• Sex-Specific Markers of Neuroinflammation and Neurodegeneration in the Spinal Cord Proteome of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis.

  2025cites this paper
• Targeting N-Methyl-d-Aspartate Receptors in Neurodegenerative Diseases

  2024cites this paper
• New developments in pre-clinical models of ALS to guide translation.

  2024cites this paper
• Neuronal DSCAM regulates the peri-synaptic localization of GLAST in Bergmann glia for functional synapse formation

  2024cites this paper
• Glutamatergic Neurotransmission in Aging and Neurodegenerative Diseases: A Potential Target to Improve Cognitive Impairment in Aging.

  2024cites this paper
• A novel KCNC3 gene variant in the voltage-dependent Kv3.3 channel in an atypical form of SCA13 with dominant central vertigo

  2024cites this paper
• An In Vivo Electroencephalographic Analysis of the Effect of Riluzole against Limbic and Absence Seizure and Comparison with Glutamate Antagonists

  2023cites this paper
• Current State and Future Directions in the Therapy of ALS

  2023cites this paper
• Amyotrophic Lateral Sclerosis and Serum Lipid Level Association: A Systematic Review and Meta-Analytic Study

  2023cites this paper
• Thiazole Derivatives as Modulators of GluA2 AMPA Receptors: Potent Allosteric Effects and Neuroprotective Potential

  2023cites this paper
• Do long‐lasting effects of epidural polarization of afferent fibres depend on persistent sodium current?

  2023cites this paper
• Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS

  2023cites this paper
• Glial Glutamate Transporter-Mediated Plasticity: System xc-/xCT/SLC7A11 and EAAT1/2 in Brain Diseases.

  2023cites this paper
• Update on neurobiological mechanisms of fear: illuminating the direction of mechanism exploration and treatment development of trauma and fear-related disorders

  2023cites this paper
• Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review

  2023cites this paper
• Alternative Targets for Modulators of Mitochondrial Potassium Channels

  2022cites this paper
• Amyotrophic lateral sclerosis

  2022cites this paper
• Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation

  2022cites this paper
• Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Current Clinical Data and Future Directions

  2021cites this paper
• Anti-allodynic and promotive effect on inhibitory synaptic transmission of riluzole in rat spinal dorsal horn

  2021cites this paper
• Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: opportunities for novel therapeutics development.

  2021cites this paper
• Memantine and Riluzole Exacerbate, Rather Than Ameliorate Behavioral Deficits Induced by 8-OH-DPAT Sensitization in a Spatial Task

  2021cites this paper
• Pharmacological and non-pharmacological management of spinocerebellar ataxia: A systematic review

  2021cites this paper
• Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

  2020cites this paper
• Emerging therapies in Friedreich’s Ataxia

  2020cites this paper
• Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway

  2020cites this paper
• An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy‐induced peripheral neuropathy, based on preclinical studies in rodent models

  2020cites this paper
• Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises

  2020cites this paper
• Time is spine: a review of translational advances in spinal cord injury.

  2019cites this paper
• Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials

  2019cites this paper
• Riluzole blocks HU210-facilitated ventral tegmental long-term depression by enhancing glutamate uptake in astrocytes.

  2019cites this paper
• 2+ -activated K + channels modulate microglia affecting motor neuron survival in hSOD1 G93A mice”

  2019cites this paper
• Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System

  2019cites this paper
• Administration of riluzole to the basolateral amygdala facilitates fear extinction in rats.

  2018cites this paper
• Post‐reexposure administration of riluzole attenuates the reconsolidation of conditioned fear memory in rats

  2018cites this paper
• Dipeptide Prodrugs of the Glutamate Modulator Riluzole.

  2018cites this paper
• Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model

  2018cites this paper
• Periaqueductal gray glutamatergic, cannabinoid and vanilloid receptor interplay in defensive behavior and aversive memory formation

  2018cites this paper
• Anticonvulsants lamotrigine and riluzole disrupt maternal behavior in postpartum female rats

  2018influential citation
• Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer

  2017cites this paper
• Functional identification of activity‐regulated, high‐affinity glutamine transport in hippocampal neurons inhibited by riluzole

  2017cites this paper
• Design, synthesis, anticonvulsant evaluation and docking study of 2-[(6-substituted benzo[d]thiazol-2-ylcarbamoyl)methyl]-1-(4-substituted phenyl)isothioureas.

  2017cites this paper
• Administration of riluzole into the basolateral amygdala has an anxiolytic‐like effect and enhances recognition memory in the rat

  2017cites this paper
• Applications of antisense oligonucleotides in designing a therapy for spinal muscular atrophy

  2017cites this paper
• Correction: Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications

  2017cites this paper
• REPROGRAMMING ASTROCYTES INTO FUNCTIONAL NEURONS FOR SPINAL CORD REPAIR

  2017cites this paper
• Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks

  2017cites this paper
• Riluzole But Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral Sclerosis

  2017cites this paper
• Effekte pharmakologischer Interventionen auf Muskelatrophie im Mausmodell der amyotrophen Lateralsklerose (ALS)

  2017influential citation
• Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications

  2017cites this paper
• The effect of riluzole alone and in combination with sodium valproate on pentylenetetrazole induced seizures in swiss-albino rats

  2016cites this paper
• Mechanistic Studies of Capsaicin‐Induced Apnea in Rodents

  2016cites this paper
• Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1

  2016cites this paper
• Combined Treatment of an Amyotrophic Lateral Sclerosis Rat Model with Recombinant GOT1 and Oxaloacetic Acid: A Novel Neuroprotective Treatment

  2015cites this paper
• Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain

  2015cites this paper
• Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside

  2015cites this paper
• Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial

  2015cites this paper
• Systemic administration of riluzole enhances recognition memory and facilitates extinction of fear memory in rats.

  2015cites this paper
• Aptamers Targeting a Subunit or a Conformation of Glutamate Ion Channel Receptors

  2013cites this paper
• Delayed Post-Injury Administration of Riluzole Is Neuroprotective in a Preclinical Rodent Model of Cervical Spinal Cord Injury

  2013cites this paper
• GRM1, A POTENTIAL TARGET FOR HUMAN MELANOMA

  2013cites this paper
• Cancer Genes and Genomics Functional Effects of GRM 1 Suppression in Human Melanoma Cells

  2012cites this paper
• Functional Effects of GRM1 Suppression in Human Melanoma Cells

  2012cites this paper
• Riluzole Treatment Reduces Motoneuron Death Induced by Axotomy in Newborn Rats

  2012cites this paper
• Pharmacological investigation of memory restorative effect of riluzole in mice

  2012cites this paper
• Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.

  2012cites this paper
• A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade?

  2011cites this paper
• Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

  2011cites this paper
• Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development

  2010cites this paper
• The neuroprotective actions of quercetin

  2010cites this paper
• Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat.

  2009cites this paper
• Neurotransmitter evaluation in the hippocampus of rats after intracerebral injection of TsTX scorpion toxin

  2009cites this paper
• Optical Analysis of [Ca 2+ ]i and Mitochondrial Signaling Pathways: Implications for the Selective Vulnerability of Motoneurons in Amyotrophic Lateral Sclerosis (ALS)

  2009cites this paper
• Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

  2009cites this paper
• Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro

  2008influential citation
• Anti-glutamatergic effect of riluzole: comparison with valproic acid.

  2007cites this paper
• Placebo‐controlled trial of riluzole in multiple system atrophy

  2006cites this paper
• Cataleptic activity of the denatured venom of the social wasp Agelaia vicina (Hymenoptera, Vespidae) in Rattus norvegicus (Rodentia, Muridae).

  2006cites this paper
• Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.

  2006cites this paper
• SEROTONERGIC MECHANISMS IN AMYOTROPHIC LATERAL SCLEROSIS

  2006cites this paper
• Glutamate modulators as novel interventions for mood disorders.

  2005cites this paper
• Role of spinal cord glutamate transporter during normal sensory transmission and pathological pain states

  2005cites this paper
• Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice.

  2004influential citation
• Interactions between riluzole and conventional antiepileptic drugs – a comparison of results obtained in the subthreshold method and isobolographic analysis

  2004influential citation
• Riluzole restores motor activity in rats with post-traumatic peripheral neuropathy.

  2004cites this paper
• Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology

  2004cites this paper
• The role of apoptosis in in vitro and in vivo models of amyotrophic lateral sclerosis.

  2004cites this paper
• Loss of color vision during long-term treatment with pramipexole

  2003cites this paper
• Effect of Riluzole on MK-801 and Amphetamine-Induced Hyperlocomotion

  2003cites this paper
• Regulation of Cellular Plasticity Cascades in the Pathophysiology and Treatment of Mood Disorders

  2003cites this paper
• Effect of Riluzole on Cytosolic Ca2+ Increase in Human Osteosarcoma Cells

  2002cites this paper
• Effect of riluzole on the acquisition and expression of amygdala kindling.

  2001cites this paper
• Effect of the neuroprotective agent riluzole on intracellular Ca2+ levels in IMR32 neuroblastoma cells

  2001cites this paper
• Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice

  2000cites this paper
• Traitement de la sclerose laterale amyotrophique avec une association de riluzole et d'un antagoniste des recepteurs ampa

  2000cites this paper
• 3-Nitropropionic acid and similar nitrotoxins.

  2000cites this paper
• Deramciclane inhibits N-methyl-D-aspartate receptor function.

  2000cites this paper